Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The validation of new CHD1L inhibitors as a therapeutic strategy for cancer.
Clune S, Awolade P, Zhou Q, Esquer H, Matter B, Kearns JT, Kellett T, Akintayo DC, Kompella UB, LaBarbera DV. Clune S, et al. Among authors: esquer h. Biomed Pharmacother. 2024 Jan;170:116037. doi: 10.1016/j.biopha.2023.116037. Epub 2023 Dec 20. Biomed Pharmacother. 2024. PMID: 38128184 Free PMC article.
HTS discovery of PARP1-HPF1 complex inhibitors in cancer.
Kellett T, Noor R, Zhou Q, Esquer H, Sala R, Stojanovic P, Rudolph J, Luger K, LaBarbera DV. Kellett T, et al. Among authors: esquer h. SLAS Discov. 2023 Dec;28(8):394-401. doi: 10.1016/j.slasd.2023.10.003. Epub 2023 Oct 14. SLAS Discov. 2023. PMID: 37844763 Free PMC article.
High-Content Drug Discovery Targeting Molecular Bladder Cancer Subtypes.
Rinaldetti S, Zhou Q, Abbott JM, de Jong FC, Esquer H, Costello JC, Theodorescu D, LaBarbera DV. Rinaldetti S, et al. Among authors: esquer h. Int J Mol Sci. 2022 Sep 14;23(18):10605. doi: 10.3390/ijms231810605. Int J Mol Sci. 2022. PMID: 36142576 Free PMC article.
Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L.
Prigaro BJ, Esquer H, Zhou Q, Pike LA, Awolade P, Lai XH, Abraham AD, Abbott JM, Matter B, Kompella UB, Messersmith WA, Gustafson DL, LaBarbera DV. Prigaro BJ, et al. Among authors: esquer h. J Med Chem. 2022 Mar 10;65(5):3943-3961. doi: 10.1021/acs.jmedchem.1c01778. Epub 2022 Feb 22. J Med Chem. 2022. PMID: 35192363 Free PMC article.
First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer.
Abbott JM, Zhou Q, Esquer H, Pike L, Broneske TP, Rinaldetti S, Abraham AD, Ramirez DA, Lunghofer PJ, Pitts TM, Regan DP, Tan AC, Gustafson DL, Messersmith WA, LaBarbera DV. Abbott JM, et al. Among authors: esquer h. Mol Cancer Ther. 2020 Aug;19(8):1598-1612. doi: 10.1158/1535-7163.MCT-20-0106. Epub 2020 Jun 4. Mol Cancer Ther. 2020. PMID: 32499299 Free PMC article.
14 results